Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense
oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in
combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma.
Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell
carcinoma.